Indonesia gains momentum as drug firms eye second year of phased national insurance
11 March 2015
Indonesia could be the new darling of healthcare industry investors, many of whom are already taking advantage of opportunities afforded by a new national health plan initiated at the beginning of last year.
7 CEOs Say It's About The "Bios": Biotechs, Biopharmaceuticals and Biosimilars
11 March 2015
It’s the booming “Bios” – biotechs, biopharmaceuticals and biosimilars – spurring capital expenditures and technology advancements, supply-and-demand questions and business decisions that grab the attention of our CEOs they are seeing in 2015.
Need to know which drugs are in short supply? FDA has an app for that
11 March 2015
The FDA has found it difficult to keep the total number of drug shortages from growing, but the agency figures it can at least help healthcare providers more easily track them. To do that it has released a mobile app that will allow anyone to use a smartphone to look up current shortages and discontinuations as well as shortages that have been resolved.
Major policy shift on costs and safety views as China moves to lift price controls on drugs
11 March 2015
China Premier Li Keqiang said the government will lift price controls on pharmaceuticals, which would mark a dramatic change of tack in efforts to both widen access to medicines from the cities into the countryside while keeping spending in check.
New Report Highlights a Decade of Innovation in Rare Diseases
11 March 2015
While any given rare disease affects fewer than 200,000 people in the U.S., rare diseases cumulatively affect 1 in 10 Americans and an estimated 350 million people worldwide.
10 March 2015
Recent trends in funding may lead young scientists to shy away from research careers, National Institutes of Health Director Francis Collins warns.
Biopharma's new normal: Constant makeovers leave R&D jobs at permanent risk
10 March 2015
Every year when I'm assessing the top trends in the industry, R&D restructuring can be relied on to make the top 5. Four years ago, Pfizer ($PFE) sent shockwaves through the industry when it announced plans to close its R&D complex in Sandwich--later it decided to keep some operations--while scaling back dramatically in Connecticut. Roche ($RHHBY) followed with its plan to close Nutley, NJ, and companies like Sanofi ($SNY) and GlaxoSmithKline ($GSK) set out to find some new approach to R&D that could justify their multibillion-dollar annual investments. Merck ($MRK) was one of the last to finally give in to the trend.
Broadly positive reactions roll in for FDA's drug shortages app
10 March 2015
The FDA made its first move into the world of smartphone apps this week with a tool to allow users of iOS and Android devices to view information on drug shortages. And the reception to the app was broadly positive, with users praising the tool itself and the FDA for pushing into the mobile sector.
Med tech industry's expenditure on lobbying at an all-time high
10 March 2015
The medical device tax is costing the med tech industry money--and so is lobbying to get rid of it. At almost $33 million, the industry's 2014 lobbying expenditure was up 6% over 2013 and has more than tripled since 1998's total of $8.9 million, Mass Devicereports, citing the Center for Responsive Politics' website, OpenSecrets.org.
09 March 2015
Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in prostate cancer, announced today they have entered into a collaboration to apply Epic's circulating tumor cell (CTC) technology in multiple investigator-initiated clinical trials to advance the development of new prostate cancer treatments.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024